US Patent

US10085958 — Bromfenac bioavailability

Formulation · Assigned to Bausch and Lomb Pharma Holdings Corp · Expires 2032-11-19 · 7y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations and methods that enhance bromfenac penetration into ocular tissue when topically administered.

USPTO Abstract

Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAYâ¢ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.

Drugs covered by this patent

bromfenac-sodium (BROMFENAC SODIUM)

Patent Metadata

Patent number: US10085958
Jurisdiction: US
Classification: Formulation
Expires: 2032-11-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Bausch and Lomb Pharma Holdings Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.